Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-04-24 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司董事会审计委员会监督德勤华永会计师事务所（特殊普通合伙）履职情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee of Chengdu Lead Drug Development Co., Ltd. regarding the supervision of Deloitte Huayong CPA Firm's audit work for the year 2023. It details the audit firm's qualifications, the process of reappointment, the committee's oversight activities, and an overall evaluation of the audit work performed. The document references the 2023 annual audit and the 2023 annual report but does not contain the actual financial statements or audit report itself. It is a supervisory report on the audit process and the audit firm's performance, which fits the definition of an Audit Report / Information (AR) filing rather than a full Annual Report (10-K) or a simple announcement. The length and content indicate it is a substantive report on audit oversight.
2024-04-24 Chinese
成都先导药物开发股份有限公司第二届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the second board of directors of Chengdu Lead Drug Development Co., Ltd. It includes approvals of the 2023 annual report and its summary, 2023 financial statements audited by Deloitte, 2023 profit distribution plan, internal control evaluation report, 2024 first quarter report, remuneration plans for 2024, and other governance and financial matters. The document repeatedly states that these reports and announcements are published separately on the Shanghai Stock Exchange website and that the board meeting resolutions will be submitted to the shareholders' meeting for approval. The document itself is a board meeting resolution announcement, not the actual annual report or quarterly report. It contains no substantive financial data or full report content but references these reports as published elsewhere. Therefore, it is best classified as Board/Management Information (MANG) because it announces board meeting decisions and management resolutions regarding financial reports and other corporate governance matters.
2024-04-24 Chinese
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2021年限制性股票激励计划部分限制性股票作废事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain restricted stocks under a 2021 stock incentive plan of Chengdu Lead Drug Development Co., Ltd. It details the legal compliance, approvals, and authorizations related to the cancellation of unvested restricted shares due to employee departures and unmet performance targets. The document references regulatory rules and disclosure obligations but does not contain financial statements or earnings data. It is a legal and regulatory compliance document related to stock incentive plan adjustments rather than a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance/legal opinion document that does not fit other specific categories.
2024-04-24 Chinese
成都先导药物开发股份有限公司董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content focuses on governance and compliance with independence rules for board members, rather than financial results, audit, or management changes. It is not a report of financial performance or an announcement of a meeting or vote. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short but contains substantive governance content, so it is not a mere announcement (RPA) or regulatory filing (RNS).
2024-04-24 Chinese
成都先导药物开发股份有限公司关于召开2023年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of Chengdu Lead Drug Development Co., Ltd. It includes information about the meeting date, voting methods, agenda items to be discussed and voted on, and procedural details for shareholders. The document does not contain the actual annual report or financial statements but rather serves as a formal notification to shareholders about the AGM and the matters to be considered. The document length is under 5,000 characters, and it is clearly a meeting notice rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-24 Chinese
成都先导药物开发股份有限公司2023年度独立董事述职报告（薛军福）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and evaluation of company governance and financial reporting. The content focuses on the independent director's report on their activities and oversight during the year 2023. It is not a full annual report (10-K), audit report (AR), or management report (MDA), but rather a specific report by an independent director on their duties and observations. This type of document is typically classified under Board/Management Information (MANG) as it relates to board members' roles and governance activities. The document length is 4439 characters, which is sufficient for a detailed report but not a full financial report. Therefore, the best fit is MANG with high confidence.
2024-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.